Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE.

brain hematoma infarction risk factors siderosis

Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
01 May 2024
Historique:
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 1 5 2024
Statut: aheadofprint

Résumé

In the phase 2 PACIFIC-STROKE trial (Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Noncardioembolic Stroke), asundexian, an oral factor XIa inhibitor, did not increase the risk of hemorrhagic transformation (HT). In this secondary analysis, we aimed to investigate the frequency, types, and risk factors of HT on brain magnetic resonance imaging (MRI). This was a secondary analysis of the PACIFIC-STROKE trial. Patients with mild-to-moderate acute noncardioembolic ischemic stroke were randomly assigned to asundexian or placebo plus guideline-based antiplatelet therapy. Brain MRIs were required at baseline (≤120 hours after stroke onset) and at 26 weeks or end-of-study. HT was defined using the Heidelberg classification and classified as early HT (identified on baseline MRI) or late HT (new HT by 26 weeks) based on iron-sensitive sequences. Multivariable logistic regression models were used to test factors that are associated with early HT and late HT, respectively. Of 1745 patients with adequate baseline brain MRI (mean age, 67 years; mean National Institutes of Health Stroke Scale score, 2.8), early HT at baseline was detected in 497 (28.4%). Most were hemorrhagic infarctions (hemorrhagic infarction type 1: 15.2%; HI2: 12.7%) while a few were parenchymal hematomas (parenchymal hematoma type 1: 0.4%; parenchymal hematoma type 2: 0.2%). Early HT was more frequent with longer symptom onset-to-MRI interval. Male sex, diabetes, higher National Institutes of Health Stroke Scale large (>15 mm) infarct size, cortical involvement by infarct, higher number of acute infarcts, presence of chronic brain infarct, cerebral microbleed, and chronic cortical superficial siderosis were independently associated with early HT in the multivariable logistic regression model. Of 1507 with follow-up MRI, HT was seen in 642 (42.6%) overall, including 361 patients (23.9%) with late HT (new HT: 306; increased grade of baseline HT: 55). Higher National Institutes of Health Stroke Scale, large infarct size, cortical involvement of infarct, and higher number of acute infarcts predicted late HT. About 28% of patients with noncardioembolic stroke had early HT, and 24% had late HT detectable by MRI. Given the high frequency of HT on MRI, more research is needed on how it influences treatment decisions and outcomes.

Sections du résumé

BACKGROUND UNASSIGNED
In the phase 2 PACIFIC-STROKE trial (Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Noncardioembolic Stroke), asundexian, an oral factor XIa inhibitor, did not increase the risk of hemorrhagic transformation (HT). In this secondary analysis, we aimed to investigate the frequency, types, and risk factors of HT on brain magnetic resonance imaging (MRI).
METHODS UNASSIGNED
This was a secondary analysis of the PACIFIC-STROKE trial. Patients with mild-to-moderate acute noncardioembolic ischemic stroke were randomly assigned to asundexian or placebo plus guideline-based antiplatelet therapy. Brain MRIs were required at baseline (≤120 hours after stroke onset) and at 26 weeks or end-of-study. HT was defined using the Heidelberg classification and classified as early HT (identified on baseline MRI) or late HT (new HT by 26 weeks) based on iron-sensitive sequences. Multivariable logistic regression models were used to test factors that are associated with early HT and late HT, respectively.
RESULTS UNASSIGNED
Of 1745 patients with adequate baseline brain MRI (mean age, 67 years; mean National Institutes of Health Stroke Scale score, 2.8), early HT at baseline was detected in 497 (28.4%). Most were hemorrhagic infarctions (hemorrhagic infarction type 1: 15.2%; HI2: 12.7%) while a few were parenchymal hematomas (parenchymal hematoma type 1: 0.4%; parenchymal hematoma type 2: 0.2%). Early HT was more frequent with longer symptom onset-to-MRI interval. Male sex, diabetes, higher National Institutes of Health Stroke Scale large (>15 mm) infarct size, cortical involvement by infarct, higher number of acute infarcts, presence of chronic brain infarct, cerebral microbleed, and chronic cortical superficial siderosis were independently associated with early HT in the multivariable logistic regression model. Of 1507 with follow-up MRI, HT was seen in 642 (42.6%) overall, including 361 patients (23.9%) with late HT (new HT: 306; increased grade of baseline HT: 55). Higher National Institutes of Health Stroke Scale, large infarct size, cortical involvement of infarct, and higher number of acute infarcts predicted late HT.
CONCLUSIONS UNASSIGNED
About 28% of patients with noncardioembolic stroke had early HT, and 24% had late HT detectable by MRI. Given the high frequency of HT on MRI, more research is needed on how it influences treatment decisions and outcomes.

Identifiants

pubmed: 38690666
doi: 10.1161/STROKEAHA.123.045204
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Chih-Hao Chen (CH)

Department of Clinical Neurosciences, University of Calgary, Canada (C.-H.C., F.S., E.E.S.).
Department of Neurology, National Taiwan University Hospital, Taipei (C.-H.C.).

Ashkan Shoamanesh (A)

Department of Medicine (Neurology), Population Health Research Institute, McMaster University, Hamilton, Canada. (A.S., R.G.H.).

Pablo Colorado (P)

Bayer U.S. Pharmaceuticals, Whippany, NJ (P.C.).

Feryal Saad (F)

Department of Clinical Neurosciences, University of Calgary, Canada (C.-H.C., F.S., E.E.S.).

Robin Lemmens (R)

Department of Neurology, University Hospitals Leuven, Belgium (R.L.).

Gian Marco De Marchis (GM)

Department of Neurology and Stroke Center, University Hospital of Basel and University of Basel, Switzerland (G.M.D.M.).
Neurology Department and Stroke Center, Kantonsspital St. Gallen, Switzerland (G.M.D.M.).

Valeria Caso (V)

Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Italy (V.C.).

Lizhen Xu (L)

Department of Statistics, Population Health Research Institute, McMaster University, Hamilton, Canada (L.X., L.H.).

Laura Heenan (L)

Department of Statistics, Population Health Research Institute, McMaster University, Hamilton, Canada (L.X., L.H.).

Jaime Masjuan (J)

Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain (J.M.).

Hanne Christensen (H)

Department of Neurology, University Hospital of Copenhagen, Bispebjerg, Denmark (H.C.).

Stuart J Connolly (SJ)

Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Canada. (S.J.C.).

Pooja Khatri (P)

Department of Neurology and Rehabilitation Sciences, University of Cincinnati, OH (P.K.).

Hardi Mundl (H)

Bayer AG, TA Thrombosis and Vascular Medicine, Wuppertal, Germany (H.M.).

Robert G Hart (RG)

Department of Medicine (Neurology), Population Health Research Institute, McMaster University, Hamilton, Canada. (A.S., R.G.H.).

Eric E Smith (EE)

Department of Clinical Neurosciences, University of Calgary, Canada (C.-H.C., F.S., E.E.S.).

Classifications MeSH